OPEXA WKN: A2DYQV ISIN: US00444P1084 Kürzel: P6NA Forum: Aktien Thema: Hauptdiskussion

Um halb 4 könnte hier eine erneute Rakete starten was meint ihr?

5 - 6€ könnte drin sein heute

Hab einen ziemlich hohen EK aber bleibe erstmal drin. Kleine Posi ist das Risiko Wert 👍

Das wäre meine Frage auch für die nächsten Monate ??;)

Was seht ihr heute noch fürs kursziele?

👍🏻🤣

👍🏻🤣

Guten Morgen im der heutigen Rakete 🚀🚀

http://mobile.dgap.de/dgap/News/corporate/relief-therapeutics-und-acer-therapeutics-unterzeichnen-optionsvereinbarung-fuer-die-exklusivitaet-der-verhandlung-einer-kooperations-und-lizenzvereinbarung-zur-weltweiten-entwicklung-und-vermarktung-von-acer-zur-behandlung-von-ha/?newsID=1419177

👀📌

Was ist den hier jetzt los ???!!!

Guten Morgen, bin mal mit einer kleinen Position dabei. Bin mal gespannt was hier geht

Geht nach oben 👍🏻

☀️

Acer Therapeutics: Undervalued With A Free Call Option On EDSIVO https://seekingalpha.com/article/4289799-acer-therapeutics-undervalued-free-call-option-edsivo?source=quotemedia_readmore

Second Quarter 2019 and Recent Events ACER-001 Investigational New Drug (IND) application cleared for initiation of pivotal bioequivalence bridging and taste assessment trials of ACER-001 compared to sodium phenylbutyrate Disclosed osanetant clinical development plan for patients with induced Vasomotor Symptoms (iVMS), which may include patients receiving tamoxifen treatment for breast cancer and/or leuprolide treatment for prostate cancer and/or women who elect to have prophylactic bilateral oophorectomy (surgical removal of ovaries) where Hormone Replacement Therapy (HRT) is likely contraindicated Ended the second quarter with $23.5 million in cash and cash equivalents, which the Company believes will be sufficient to fund its current operating and capital requirements through the end of 2020 Upcoming Milestones EDSIVO™ Conduct Type A meeting with FDA in Q3 2019 to discuss EDSIVO™ Complete Response Letter ACER-001: Conduct Type C meeting with FDA in 2H 2019 to discuss ACER-001 development plans Initiate ACER-001 pivotal bioequivalence bridging and taste assessment trials in Q4 2019 Submit ACER-001 New Drug Application (NDA) for UCD patients in mid-2020, assuming successful outcomes in bridging trials and sufficient drug product stability data to enable NDA filing Osanetant: Submit osanetant IND in Q4 2019 Initiate Phase 1/2 trial in mid-2020 evaluating osanetant in patients with iVMS, which may include patients receiving tamoxifen treatment for breast cancer and/or leuprolide treatment for prostate cancer and/or women who elect to have prophylactic bilateral oophorectomy (surgical removal of ovaries) where Hormone Replacement Therapy (HRT) is likely contraindicated  http://app.quotemedia.com/quotetools/newsItem.htm?webmasterId=102683&storyId=5960703527122220